Antiplatelet therapy after coronary occlusion
نویسندگان
چکیده
منابع مشابه
Antiplatelet therapy to prevent coronary artery bypass graft occlusion.
O cclusion rates after coronary artery bypass surgery rise from about 10-15% per distal anastomosis in the first month to approximately 16-26% at 1 year, 2% per year in the next 5 years, and 5% per year for the remainder of the decade. Rates are thus about 37% at 5-7 years and 55% at 12 years.1 As a result, the identification of a safe and effective medical therapy to prevent occlu-sion, such a...
متن کاملTriple Versus Dual Antiplatelet Therapy After Coronary Stenting
OBJECTIVES We evaluated safety and efficacy of triple antiplatelet therapy with aspirin, clopidogrel, or ticlopidine and cilostazol after coronary stenting. BACKGROUND Triple antiplatelet therapy might have beneficial effect to prevent thrombotic complications in patients undergoing coronary stenting. METHODS Patients undergoing successful coronary stenting were divided into dual antiplatelet t...
متن کاملApixaban with antiplatelet therapy after acute coronary syndrome.
BACKGROUND Apixaban, an oral, direct factor Xa inhibitor, may reduce the risk of recurrent ischemic events when added to antiplatelet therapy after an acute coronary syndrome. METHODS We conducted a randomized, double-blind, placebo-controlled clinical trial comparing apixaban, at a dose of 5 mg twice daily, with placebo, in addition to standard antiplatelet therapy, in patients with a recent...
متن کاملThe Development of Antiplatelet Therapy after Percutaneous Coronary Intervention
Coronary artery disease (CAD) is a common disease and has an impact in all over the word. With the development of life level and life style, the incident of morbidity and mortality largely increased [1]. Atherogenesis and the formation of thrombi are the main risk events. The application of percutaneous coronary intervention (PCI) released coronary artery disease and improved patients’ quality ...
متن کاملOptimal duration of dual antiplatelet therapy after percutaneous coronary intervention or after acute coronary syndrome
To prevent recurrent ischaemic events, dual antiplatelet therapy (DAPT) is the standard of care after percutaneous coronary intervention and in the treatment of acute coronary syndrome. Recent evidence supports an adjusted DAPT duration in selected patients.The current paper aims to encourage cardiologists to actively search for patients benefiting from either shorter or prolonged duration DAPT...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Australian Prescriber
سال: 2007
ISSN: 0312-8008,1839-3942
DOI: 10.18773/austprescr.2007.057